Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Association Between Polycystic Ovary Syndrome and Metabolic Syndrome

Author(s): Leandro Martin Velez and Alicia Beatriz Motta

Volume 21 , Issue 35 , 2014

Page: [3999 - 4012] Pages: 14

DOI: 10.2174/0929867321666140915141030

Price: $65

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder affecting women in reproductive age. Although the etiology of PCOS remains unclear, it is believed to result from genetic, environmental and behavioral interactions. Women with PCOS have higher lifetime risk for cardiovascular disease (CVR) than healthy women at the same age and tend to display insulin resistance (IR). IR has traditionally been defined as a decreased ability of insulin to mediate the metabolic actions on glucose uptake, glucose production, and/or lipolysis. This results in a requirement for increased amounts of insulin to achieve a given metabolic action.

Metabolic syndrome (MS) includes hyperinsulinemia, dyslipidemia, increased CVR and hyperleptinemia and metabolic disorders such as hypertension, IR, gestational diabetes, type 2 diabetes mellitus, systemic inflammation and endothelial dysfunction. The prevalence of MS in women is around 50 %. In addition, it has been recently suggested that women with MS show increased circulating androgens. The present review discusses the main alterations and features of PCOS and MS and the most important treatments.

Keywords: cardiovascular disease, diabetes, glitazones, hyperandrogenism, insulin resistance, lipids, metabolic syndrome, metformin, obesity, polycystic ovary syndrome, simvastatin, statins.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy